Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Status:
Completed
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
The study will evaluate the givinostat (ITF2357) potential drug-drug interaction (DDI) at
level of CYP3A-mediated metabolism and P-glycoprotein (P-gp) transport.